Covered recipient · General Payments record
WARNER W CARR
Allopathic & Osteopathic Physicians Allergy & Immunology Allergy
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$124,204.19
105 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $77,800.08 | 10 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $34,725.00 | 17 |
| Travel and Lodging | $8,032.29 | 19 |
| Food and Beverage | $2,896.82 | 58 |
| Honoraria | $750.00 | 1 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $43,694.03 | 29 |
| SANOFI-AVENTIS U.S. LLC | $31,150.00 | 1 |
| AstraZeneca Pharmaceuticals LP | $26,019.71 | 29 |
| Teva Pharmaceuticals USA, Inc. | $7,824.40 | 6 |
| Merz North America, Inc. | $6,448.22 | 9 |
| OptiNose US, Inc. | $4,529.55 | 11 |
| ALK-Abello, Inc | $4,349.79 | 8 |
| Genentech USA, Inc. | $54.89 | 3 |
| Novartis Pharmaceuticals Corporation | $31.20 | 2 |
| GENZYME CORPORATION | $24.61 | 2 |
| PFIZER INC. | $24.45 | 2 |
| Horizon Therapeutics plc | $20.42 | 1 |
| GlaxoSmithKline, LLC. | $17.50 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.42 | 1 |
Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
WARNER W CARR
NPI 1184798001 · CMS profile ID 281334
Allopathic & Osteopathic Physicians / Allergy & Immunology / Allergy
LAGUNA NIGUEL, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1184798001?year=2019&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- WARNER W CARR, NPI 1184798001, CMS profile ID 281334. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184798001?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). WARNER W CARR, NPI 1184798001, CMS profile ID 281334. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184798001?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- WARNER W CARR, NPI 1184798001, CMS profile ID 281334, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1184798001?year=2019&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
105 matching records · $124,204.19 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 105.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $47.14 | 05/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673356943 | CMS |
| Regeneron Healthcare Solutions, Inc. | $60.84 | 05/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673356945 | CMS |
| Regeneron Healthcare Solutions, Inc. | $209.32 | 05/31/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673356947 | CMS |
| Regeneron Healthcare Solutions, Inc. | $127.85 | 05/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673356949 | CMS |
| Regeneron Healthcare Solutions, Inc. | $85.00 | 05/17/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673356937 | CMS |
| OptiNose US, Inc. | $750.00 | 05/16/2019 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684243391 | CMS |
| Horizon Therapeutics plc | $20.42 | 05/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691345115 | CMS |
| Regeneron Healthcare Solutions, Inc. | $16,720.00 | 05/10/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673356935 | CMS |
| Teva Pharmaceuticals USA, Inc. | $4.26 | 05/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697710391 | CMS |
| Merz North America, Inc. | $5,687.58 | 04/26/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 689347907 | CMS |
| Merz North America, Inc. | $3.54 | 04/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 689385017 | CMS |
| Merz North America, Inc. | $0.41 | 04/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 689385019 | CMS |
| Merz North America, Inc. | $5.78 | 04/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 689385021 | CMS |
| Merz North America, Inc. | $3.35 | 04/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 689385023 | CMS |
| Merz North America, Inc. | $381.60 | 04/26/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 689387615 | CMS |
| Merz North America, Inc. | $192.66 | 04/26/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 689387617 | CMS |
| OptiNose US, Inc. | $93.85 | 04/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684243459 | CMS |
| OptiNose US, Inc. | $1,750.00 | 04/25/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684243481 | CMS |
| OptiNose US, Inc. | $28.56 | 04/25/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684243483 | CMS |
| OptiNose US, Inc. | $5.11 | 04/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684243411 | CMS |
| GENZYME CORPORATION | $6.73 | 04/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694022325 | CMS |
| PFIZER INC. | $10.91 | 04/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673819233 | CMS |
| AstraZeneca Pharmaceuticals LP | $563.72 | 04/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685807241 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,150.00 | 04/04/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685760557 | CMS |
| Novartis Pharmaceuticals Corporation | $11.71 | 04/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659193095 | CMS |
| AstraZeneca Pharmaceuticals LP | $124.47 | 03/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685297251 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.65 | 03/28/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685317125 | CMS |
| AstraZeneca Pharmaceuticals LP | $250.00 | 03/06/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685699217 | CMS |
| ALK-Abello, Inc | $165.60 | 02/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 698044775 | CMS |
| ALK-Abello, Inc | $79.50 | 02/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 698044777 | CMS |
| ALK-Abello, Inc | $59.57 | 02/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 698044779 | CMS |
| ALK-Abello, Inc | $99.37 | 02/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 698044781 | CMS |
| ALK-Abello, Inc | $59.62 | 02/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 698044783 | CMS |
| ALK-Abello, Inc | $3,000.00 | 02/21/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 698055257 | CMS |
| ALK-Abello, Inc | $750.00 | 02/21/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 698055259 | CMS |
| SANOFI-AVENTIS U.S. LLC | $31,150.00 | 02/21/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694138315 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,700.00 | 02/20/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685353159 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,150.00 | 02/20/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685356473 | CMS |
| Genentech USA, Inc. | $16.11 | 02/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681295281 | CMS |
| Novartis Pharmaceuticals Corporation | $19.49 | 02/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659193091 | CMS |
| Regeneron Healthcare Solutions, Inc. | $188.33 | 02/15/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673356931 | CMS |
| Regeneron Healthcare Solutions, Inc. | $35.25 | 02/15/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673356933 | CMS |
| GENZYME CORPORATION | $17.88 | 02/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694274445 | CMS |
| Regeneron Healthcare Solutions, Inc. | $817.50 | 02/14/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673356929 | CMS |
| OptiNose US, Inc. | $5.06 | 02/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684243373 | CMS |
| AstraZeneca Pharmaceuticals LP | $126.34 | 01/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685085867 | CMS |
| AstraZeneca Pharmaceuticals LP | $489.45 | 01/30/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685115957 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.92 | 01/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685120399 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,358.71 | 01/30/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685292689 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,074.00 | 01/28/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685224967 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $248,888.69 | 60 |
| PY2024 | Recipient | $233.64 | 1 |
| PY2024 | Principal investigator | $147,016.30 | 114 |
| PY2023 | Principal investigator | $127,766.16 | 66 |
| PY2022 | Principal investigator | $208,724.14 | 67 |
| PY2021 | Principal investigator | $462,823.75 | 71 |
| PY2020 | Recipient | $1,402.50 | 2 |
| PY2020 | Principal investigator | $413,592.51 | 73 |
| PY2019 | Recipient | $4,145.01 | 8 |
| PY2019 | Principal investigator | $217,392.92 | 22 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
60 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,385.80 | 12/01/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES OF SOUTHERN CALIFORNIA | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN | No dispute reported | 06/30/2026 | 1192152482 |
| Principal investigator 1 | ABBVIE INC. | $2,250.00 | 11/10/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | No dispute reported | 06/30/2026 | 1202523629 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $119.78 | 11/10/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190314123 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,600.00 | 11/10/2025 | Non-covered Recipient Entity Allergy Asthma Association Of Southern California,A Medical Group Inc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226092367 |
| Principal investigator 1 | ABBVIE INC. | $1,224.00 | 11/06/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202523249 |
| Principal investigator 1 | ABBVIE INC. | $2,709.00 | 11/05/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | No dispute reported | 06/30/2026 | 1202521747 |
| Principal investigator 1 | ABBVIE INC. | $392.60 | 11/04/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202520293 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $382.50 | 10/23/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF SOUTHERN CALIFORNIA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184252866 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,145.00 | 10/23/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF SOUTHERN CALIFORNIA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184252868 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $179.90 | 10/15/2025 | Non-covered Recipient Entity Allergy & Asthma Associates of Southern California dba. Southern California Research | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | No dispute reported | 06/30/2026 | 1244050458 |
| Principal investigator 1 | ABBVIE INC. | $100.00 | 10/09/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202514863 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $163.75 | 09/18/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF SOUTHERN CALIFORNIA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184240780 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $6,504.00 | 09/12/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES OF SOUTHERN CALIFORNIA | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185549043 |
| Principal investigator 1 | ABBVIE INC. | $3,817.85 | 09/04/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202509618 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $702.60 | 09/04/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF SOUTHERN CALIFORNIA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184235313 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $623.85 | 09/04/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF SOUTHERN CALIFORNIA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184235317 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,769.60 | 09/04/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF SOUTHERN CALIFORNIA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184235323 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,695.45 | 09/04/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF SOUTHERN CALIFORNIA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184235325 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,305.60 | 09/04/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF SOUTHERN CALIFORNIA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184235327 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $256.25 | 09/04/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF SOUTHERN CALIFORNIA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184235329 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $58.75 | 09/04/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF SOUTHERN CALIFORNIA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184235333 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $336.25 | 09/04/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF SOUTHERN CALIFORNIA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184235341 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $571.25 | 09/04/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF SOUTHERN CALIFORNIA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184235353 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $580.50 | 09/04/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF SOUTHERN CALIFORNIA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184235355 |
| Principal investigator 1 | ABBVIE INC. | $1,460.70 | 09/03/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202508024 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,094.60 | 09/03/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192186310 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,274.00 | 08/25/2025 | Non-covered Recipient Entity Allergy Asthma Association Of Southern California,A Medical Group Inc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226092327 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,450.00 | 08/25/2025 | Non-covered Recipient Entity Allergy Asthma Association Of Southern California,A Medical Group Inc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226092334 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $40.00 | 08/25/2025 | Non-covered Recipient Entity Allergy Asthma Association Of Southern California,A Medical Group Inc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226092340 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,000.00 | 08/25/2025 | Non-covered Recipient Entity Allergy Asthma Association Of Southern California,A Medical Group Inc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226092346 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $110.00 | 08/25/2025 | Non-covered Recipient Entity Allergy Asthma Association Of Southern California,A Medical Group Inc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226092352 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,500.00 | 08/14/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192186132 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $15,896.32 | 08/07/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES OF SOUTHERN CALIFORNIA | a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA | No dispute reported | 06/30/2026 | 1185549035 |
| Principal investigator 1 | ABBVIE INC. | $841.00 | 08/05/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202501120 |
| Principal investigator 1 | ABBVIE INC. | $410.08 | 08/05/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202501122 |
| Principal investigator 1 | ABBVIE INC. | $1,460.70 | 08/05/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202501124 |
| Principal investigator 1 | ABBVIE INC. | $314.00 | 08/05/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202502180 |
| Principal investigator 1 | ABBVIE INC. | $470.00 | 08/05/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202502182 |
| Principal investigator 1 | ABBVIE INC. | $2,794.36 | 08/05/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202502184 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,200.00 | 08/04/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192186136 |
| Principal investigator 1 | PFIZER INC. | $11,972.00 | 08/02/2025 | Non-covered Recipient Entity Allergy Asthma Associates of Southern California dba Southern California Research | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA | No dispute reported | 06/30/2026 | 1228828308 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,424.05 | 07/23/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192186154 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $310.91 | 06/24/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF SOUTHERN CALIFORNIA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184210610 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,840.50 | 06/20/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192186145 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $750.00 | 06/05/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF SOUTHERN CALIFORNIA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184204113 |
| Principal investigator 1 | ABBVIE INC. | $392.60 | 06/03/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202488395 |
| Principal investigator 1 | AstraZeneca UK Limited | $16,034.48 | 05/29/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK | a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA | No dispute reported | 06/30/2026 | 1185549039 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,368.90 | 05/21/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192186149 |
| Principal investigator 1 | ABBVIE INC. | $392.60 | 05/07/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202483143 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $392.40 | 04/23/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192186140 |
| Principal investigator 1 | ABBVIE INC. | $1,495.80 | 03/07/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202460555 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,262.39 | 03/03/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES OF SOUTHERN CALIFORNIA | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN | No dispute reported | 06/30/2026 | 1192152478 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $392.40 | 02/25/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192186123 |
| Principal investigator 1 | ABBVIE INC. | $1,495.80 | 02/06/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202448759 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,146.60 | 01/24/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK LLC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192186127 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $370.00 | 01/14/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES OF SOUTHERN CALIFORNIA | An Open-label, Multicenter, Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Eligible Subjects With CSU Who Have Participated in Preceding Studies With LOU064 | No dispute reported | 06/30/2026 | 1190307999 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $8,280.00 | 01/09/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES OF SOUTHERN CALIFORNIA | Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 | No dispute reported | 06/30/2026 | 1185549041 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $14,527.65 | 01/08/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK | Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 | No dispute reported | 06/30/2026 | 1185549037 |
| Principal investigator 1 | Eli Lilly and Company | $91,339.37 | 01/03/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB/ LY3650150 IN ADULT PARTICIPANTS WITH PERENNIAL ALLERGIC RHINITIS | No dispute reported | 06/30/2026 | 1187878017 |
| Principal investigator 1 | ABBVIE INC. | $510.20 | 01/02/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA ASSOCIATES OF | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202435161 |